XASXBTC
Market cap15mUSD
Jan 06, Last price
0.08AUD
1D
0.00%
1Q
16.92%
Jan 2017
-33.91%
Name
BTC Health Ltd
Chart & Performance
Profile
BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare and biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia. The fund invests in both listed and unlisted companies.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 16 23.38% | 13 -86.04% | 95 395.07% | |||||||
Cost of revenue | 550 | |||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 16 | 13 | (455) | |||||||
NOPBT Margin | 100.00% | 100.00% | ||||||||
Operating Taxes | (492) | |||||||||
Tax Rate | ||||||||||
NOPAT | 16 | 13 | 37 | |||||||
Net income | 1,055 -110.38% | (10,168) 1,665.02% | (576) 47.08% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 888 | 2,300 | ||||||||
BB yield | -7.38% | -20.40% | ||||||||
Debt | ||||||||||
Debt current | 150 | |||||||||
Long-term debt | ||||||||||
Deferred revenue | 105 | 105 | 105 | |||||||
Other long-term liabilities | (105) | (105) | (105) | |||||||
Net debt | (4,937) | (2,937) | (12,840) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (405) | (434) | (393) | |||||||
CAPEX | (3) | |||||||||
Cash from investing activities | (198) | (2,206) | ||||||||
Cash from financing activities | 888 | 2,400 | ||||||||
FCF | 16 | 8 | 3 | |||||||
Balance | ||||||||||
Cash | 2,022 | 1,737 | 2,170 | |||||||
Long term investments | 2,915 | 1,200 | 10,820 | |||||||
Excess cash | 4,936 | 2,936 | 12,986 | |||||||
Stockholders' equity | 4,945 | 2,780 | 12,862 | |||||||
Invested Capital | 9 | (105) | 150 | |||||||
ROIC | 58.35% | 2.73% | ||||||||
ROCE | 0.33% | 0.50% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 316,459 | 281,846 | 281,846 | |||||||
Price | 0.04 46.15% | 0.03 -35.00% | 0.04 -45.95% | |||||||
Market cap | 12,025 64.10% | 7,328 -35.00% | 11,274 -38.10% | |||||||
EV | 7,088 | 4,391 | (1,566) | |||||||
EBITDA | 16 | 13 | (455) | |||||||
EV/EBITDA | 433.28 | 331.15 | 3.45 | |||||||
Interest | ||||||||||
Interest/NOPBT |